The rise of the genome and personalised medicine

Authors: Helen K Brittain, Richard Scott and Ellen Thomas

Virtually all medical specialties are impacted by genetic disease. Enhanced understanding of the role of genetics in human disease, coupled with rapid advancement in sequencing technology, is transforming the speed of diagnosis for patients and providing increasing opportunities to tailor management. As set out in the Annual report of the Chief Medical Officer 2016: Generation Genome and the recent NHS England board paper Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments, the increasing ‘mainstreaming’ of genetic testing into routine practice and plans to embed whole genome sequencing in the NHS mean that the profile and importance of genomics is on the rise for many clinicians. This article provides a brief overview of genomics and its current clinical applications, including its contribution to personalised medicine. Physicians will be signposted to key issues that will allow the successful implementation of genomics for rare disease diagnosis and cancer management.

The rise of genomics

Genomic medicine has the capacity to revolutionise the healthcare of an individual with a rare disease or cancer by offering prompt and accurate diagnosis, risk stratification based upon genotype and the capacity for personalised treatments.

Deciphering the genome

The human genome comprises in excess of 3 billion DNA base pairs. It was first mapped through the Human Genome Project, an extensive international collaboration over 13 years. Advances in sequencing technology (known as ‘next generation sequencing’) have enabled a genome to be sequenced within hours, at a fraction of the initial cost, resulting in widespread application for diagnosis and research. Previously, individual genes were sequenced exon by exon, using capillary electrophoresis (Sanger sequencing). Despite the speed and automation involved in the sequencing itself, considerable input is required in the interpretation of the results, meaning that clinically useful information is typically provided through diagnostic laboratories in 2–12 weeks, depending on clinical urgency. Fig 1 and Table 1 provide an overview and comparison of the approaches using newer sequencing technology: whole genome sequencing (WGS), whole exome sequencing and targeted sequencing of genes via a static ‘panel’.

The genome and rare disease

There are an estimated 6,000 rare diseases, each defined as affecting less than 1 in 2,000 people. In the UK, these cumulatively affect 3.5 million people equating to a 1 in 17 lifetime risk. 80% are estimated to have genetic origins. These include conditions with a virtually exclusive Mendelian genetic aetiology and rare Mendelian subsets within common disorders (eg familial hypercholesterolaemia). In some disorders, highly targeted genetic testing remains best, for example cystic fibrosis, which is readily identifiable clinically with a single causative gene. In an increasing number of clinical settings, broader-based genetic investigation – such as gene panels, exome sequencing

Key points

Genomic approaches offer the capacity to understand the breadth of rare disease and cancer, including those that are exclusively genetic, common diseases with a Mendelian subset, polygenic complex conditions and somatic mosaic conditions.

- The applications of personalised medicine are numerous and exciting and are growing, but the evidence base and impact of each intervention requires thorough analysis.
- Every human genome contains around 3–5 million genetic variants compared with the reference sequence. Caution is therefore required in analysing genomic results and attributing causation for any given variant; expert interpretation, preferably in a multi-disciplinary setting is required.
- Detailed clinical information, in terms of phenotype and family structure, remains key in interpreting genetic variation.
- It is important that patients and clinicians do not see a negative genomic test result as a ‘clean bill of health’.

KEYWORDS: Ethics, genomics, personalised medicine, variant classification and whole genome sequencing.
and WGS – is recognised as advantageous, particularly where the phenotype is variable or non-specific and the range of plausibly causative genes is wide. Table 2 gives examples of how patients can benefit from WGS. In addition, WGS can detect non-coding variants that disrupt regulatory control of gene expression and potentially uncover novel disease mechanisms.

The genome and cancer

Cancer is a genetic disease resulting from an accumulation of mutations in a particular tissue (the soma) causing uncontrolled cell division. Sequencing DNA extracted from a tumour constructs a picture of the mutational events and drivers for oncogenesis. These somatic genomic mutations can direct therapy based on likely tumour response. Abbosh et al. outline the potential role in sequencing circulating tumour DNA (ctDNA), which is separate from cellular DNA, to identify tumour recurrence in advance of conventional imaging modalities. This could offer a therapeutic window of opportunity and the potential to identify further mutations within the ctDNA sequence, indicating the development of chemotherapeutic resistance.
Sequencing an individual’s constitutional DNA (their germline) reveals inherited cancer predisposition syndromes, conferring considerable lifetime risk of malignancy. Many of these are heritable as autosomal dominant traits and may therefore direct treatment choices, as well as surveillance, for family members.

The genome and common disease

In time, with access to large genomic datasets, the capacity to understand complex disease predisposition through multiple small-effect genetic variants, coupled with environmental interaction, will evolve. Currently, there are very few clinical settings where testing for such variants alters management.

Communicating genomics and ethical considerations

Genomic test results have potential implications for the sequenced individual, their family and future generations. Although there is currently no single accepted approach, it is increasingly becoming standard practice to consider categorising the potential findings:

> pertinent (primary) findings – those related to the original reason for the test, providing a diagnosis.

| Approach | Definition | Advantages | Disadvantages |
|-----------|------------|------------|---------------|
| Whole genome sequencing (WGS) | Sequencing of the entire genome | > Comprehensive  
> Even coverage enabling identification of dosage abnormalities/structural rearrangements  
> Detects non-coding variants  
> Potential to detect disorders caused by DNA repeats, including Fragile X, myotonic dystrophy  
> Able to detect mitochondrial mutations | > Expensive  
> Millions of variants, which can be difficult to interpret  
> Relatively shallow sequencing (fewer reads per gene), which can affect sensitivity; however, this is improving as technology advances  
> Need a clear system to deal with additional findings |
| Whole exome sequencing (WES) or clinical exome sequencing | Sequencing of the exons (coding region) of genes or sequencing of the exons of known disease genes | > Cheaper than WGS  
> Analysis not restricted to genes known to cause a given condition  
> Fewer variants than WGS so easier to interpret  
> Deep sequencing increases sensitivity  
> Able to detect mitochondrial mutations | > Less even coverage of the genome, therefore dosage abnormalities are more difficult to detect  
> Only 1–2% of the genome is covered  
> Need a clear system to deal with additional findings |
| Targeted gene sequencing via a static gene panel | Sequencing of a specific list of pre-determined genes that are known to cause a particular phenotype | > Cost effective  
> Very deep sequencing  
> Fewer variants detected so data easier to interpret | > Difficult to add new genes to the panel as they are discovered as this requires a redesign of the capture process  
> Less even coverage of the subset of genes, therefore dosage abnormalities are harder to detect  
> Patients do not benefit from additional health findings |

### Table 1. A comparison of whole genome sequencing, whole exome sequencing and static gene panel techniques

| Approach | Definition | Advantages | Disadvantages |
|-----------|------------|------------|---------------|
| Whole genome sequencing (WGS) | Sequencing of the entire genome | > Comprehensive  
> Even coverage enabling identification of dosage abnormalities/structural rearrangements  
> Detects non-coding variants  
> Potential to detect disorders caused by DNA repeats, including Fragile X, myotonic dystrophy  
> Able to detect mitochondrial mutations | > Expensive  
> Millions of variants, which can be difficult to interpret  
> Relatively shallow sequencing (fewer reads per gene), which can affect sensitivity; however, this is improving as technology advances  
> Need a clear system to deal with additional findings |
| Whole exome sequencing (WES) or clinical exome sequencing | Sequencing of the exons (coding region) of genes or sequencing of the exons of known disease genes | > Cheaper than WGS  
> Analysis not restricted to genes known to cause a given condition  
> Fewer variants than WGS so easier to interpret  
> Deep sequencing increases sensitivity  
> Able to detect mitochondrial mutations | > Less even coverage of the genome, therefore dosage abnormalities are more difficult to detect  
> Only 1–2% of the genome is covered  
> Need a clear system to deal with additional findings |
| Targeted gene sequencing via a static gene panel | Sequencing of a specific list of pre-determined genes that are known to cause a particular phenotype | > Cost effective  
> Very deep sequencing  
> Fewer variants detected so data easier to interpret | > Difficult to add new genes to the panel as they are discovered as this requires a redesign of the capture process  
> Less even coverage of the subset of genes, therefore dosage abnormalities are harder to detect  
> Patients do not benefit from additional health findings |

Sequencing an individual’s constitutional DNA (their germline) reveals inherited cancer predisposition syndromes, conferring considerable lifetime risk of malignancy. Many of these are heritable as autosomal dominant traits and may therefore direct treatment choices, as well as surveillance, for family members.

### Table 2. Cases reported in the NHS England Board paper demonstrating a benefit from WGS

| Demographics | Diagnosis | Method of diagnosis | Benefit |
|--------------|-----------|---------------------|---------|
| 4-year-old girl | Glut1 deficiency syndrome | WGS via 100,000 genomes project | Specialised treatment with a low-carbohydrate diet has led to symptomatic improvement |
| Three sisters with breast cancer | Breast cancer | Clinical diagnosis. No mutations identified in BRCA1 and BRCA2 genes on the NHS | Ongoing active participation in research via the 100,000 genomes project to further the knowledge of the causes of breast cancer |
| 10-year-old girl | Life threatening chickenpox infection; CTP51 mutations identified | WGS via 100,000 genomes project | Understanding about why she is prone to infections. Altered her management as she is being considered for a bone marrow transplant as a potential cure |
| 29-year-old man | Severe learning disability; mutation identified in a new disease gene | WGS via 100,000 genomes project | Understanding the cause for his difficulties. Reassurance for family members that the new mutation in him is unlikely to affect the wider family |
Interpreting genomic data

Understanding variation within the human genome, to differentiate 'normal' from disease-causing variants, is challenging. Every human genome contains around 3–5 million genetic variants compared with the reference sequence. The vast majority of rare variants in the genome have no link to a patient's disorder. Positive evidence needs to be sought as to the pathogenicity for any given variant, accompanied by consideration of the phenotype, family structure and inheritance pattern. Therefore, a multidisciplinary approach including clinical scientists and clinicians is recommended. UK diagnostic genetics laboratories are adopting variant classification guidelines from the ACMG.\(^\text{10}\) Accuracy is vital given the potential harm – not just for the individual, but also family members and perhaps future generations – if an inaccurate diagnosis is made.

Increasingly, large databases of genomes across different ethnic populations, from sources including GnoMAD\(^\text{11}\) and the 100,000 genomes project,\(^\text{12}\) will improve the accuracy of interpretation.

Health Education England provide a range of courses on genomics, from formal qualifications through to continuing personal and professional development modules (www.genomicseducation.hee.nhs.uk/taught-courses).

Personalised medicine

Personalised medicine represents a shift in approach from 'one-size-fits-all' to tailored care and targeted therapies.\(^\text{13}\) The application of new technologies, including genomics, enhances our understanding of disease and its molecular mechanisms, and therefore the capacity for personalised interventions. Increasingly, other testing modalities will contribute, including transcriptomics (RNA-based testing), metabolomics (analysing the metabolites present in an individual) and proteomics (analysing the entire complement of expressed proteins).

Prediction and prevention of disease

An important example in prediction and prevention of disease is familial hypercholesterolaemia, where heterozygous gene mutations are expected in 1:500 of the population.\(^\text{14}\) This confers a high risk of cardiovascular disease and is inherited in an autosomal dominant manner. Risk-reducing treatments have been recommended by the National Institute for Health and Care Excellence (NICE) since 2007 (Table 3).

Molecular diagnosis and familial cascade testing by genotype identify those who warrant aggressive lipid-lowering therapy, representing an exciting step towards primary prevention. More families with familial hypercholesterolaemia will be identified through analysis of secondary findings from genomic tests for unrelated conditions.

Targeted therapy based on efficacy

There are long-standing examples of germline findings, such as BRCA1 and BRCA2 mutations, used in the oncological setting to predict the natural history of disease and enable individualised choice regarding risk-reduction. Increasingly, these results also direct therapeutic strategies.

The cancer, or somatic, genome can predict therapeutic response through an understanding of the molecular implications of certain mutations. For example, in malignant melanoma, the BRAF V600E mutation is common and results in constitutive activation of downstream signalling pathways,\(^\text{15}\) leading to cellular proliferation. Vemurafenib, an inhibitor of mutated BRAF, has been shown to improve overall survival and progression-free survival compared with standard therapy,\(^\text{15}\) leading to its recommendation by NICE. Table 3 summarises all NICE approvals by genotype (germline and somatic).

Development of new targeted therapies

A number of conditions have progressed through the cycle of gene discovery, pathogenesis research and development of a novel treatment, leading to clinical trials. One such example is the delineation of FGFR3 signalling pathways and mechanism of reduced bone formation in achondroplasia. This has led to phase III clinical trials for BMN111\(^\text{16}\) after promising pre-clinical and earlier phase studies,\(^\text{17}\) which suggest this treatment improves bone growth.

Pharmacogenetics to minimise the risk of adverse events

Genetic variation is already used to predict treatment response or adverse effects across a number of clinical areas. An example of this isabacavir treatment in HIV, where genotype can predict the risk of a severe adverse reaction.\(^\text{18}\) Selection of an alternative anti-retroviral drug in those at risk has been shown to be an effective strategy.
| Technology appraisal number | Year of publication | Relevant genome | Technology | Condition | Categorisation | Comment |
|-----------------------------|---------------------|----------------|------------|-----------|---------------|---------|
| TA 358                      | 2015                | Germline       | Tolvaptan  | Treating autosomal dominant polycystic kidney disease | Optimised | Optimised recommendation for tolvaptan as an option for treating autosomal dominant polycystic kidney disease in adults to slow the progression of cyst development and renal insufficiency, only if:  
  - they have chronic kidney disease stage 2 or 3 at the start of treatment  
  - there is evidence of rapidly progressing disease and the company provides it with the discount agreed in the patient access scheme. |
| TA 381                      | 2016                | Germline       | Olaparib   | Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy | Optimised | Optimised recommendation for olaparib as an option for treating adults with relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum-based chemotherapy, only if:  
  - they have had three or more courses of platinum-based chemotherapy and  
  - the drug cost of olaparib for people who remain on treatment after 15 months will be met by the company. |
| TA 385 (&TA132)             | 2016 (2007)         | Germline       | Ezetimibe monotherapy | Treating primary heterozygous-familial and non-familial hypercholesterolaemia | Recommended | Recommended in line with marketing authorisation. |
| TA 385 (&TA132)             | 2016 (2007)         | Germline       | Ezetimibe co-administered with initial statin therapy | Treating primary heterozygous-familial and non-familial hypercholesterolaemia | Recommended | Recommended in line with marketing authorisation. |
| TA 393                      | 2016                | Germline       | Alirocumab | Treating primary hypercholesterolaemia and mixed dyslipidaemia | Optimised | Optimised recommendation for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:  
  Low-density lipoprotein concentrations are persistently above the thresholds specified despite maximal tolerated lipid-lowering therapy.  
  That is, either the maximum dose has been reached or further titration is limited by intolerance (as defined in the NICE guideline for familial hypercholesterolaemia), and the company provides alirocumab with the discount agreed in the patient access scheme. |
| TA 394                      | 2016                | Germline       | Evolocumab | Treating primary hypercholesterolaemia and mixed dyslipidaemia | Optimised | Optimised recommendation for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:  
  The dosage is 140 mg every 2 weeks. |
### Table 3. (Continued)

| Technology appraisal number | Year of publication | Relevant genome | Technology | Condition | Categorisation | Comment |
|-----------------------------|---------------------|----------------|------------|-----------|----------------|---------|
| TA251 2012                  | Somatic             | Nilotinib (first line) | Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukemia | Recommended | Recommendation in line with marketing authorisation and following agreement of patient access scheme |
| TA251 2012                  | Somatic             | Standard-dose imatinib (first line) | Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukemia | Recommended | Partial update of TA70. Recommendation in line with marketing authorisation. |
| TA269 2012                  | Somatic             | Vemurafenib | Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma | Recommended | Recommendation in line with marketing authorisation and following agreement of patient access scheme. |
| TA321 2014                  | Somatic             | Dabrafenib | Unresectable or metastatic BRAF V600 mutation-positive melanoma | Recommended | Recommendation in line with marketing authorisation and following agreement of patient access scheme. |
| TA322 2014                  | Somatic             | Lenalidomide | Myelodysplastic syndromes associated with an isolated deletion 5q cytogenic abnormality | Recommended | Recommendation in line with marketing authorisation and following agreement of patient access scheme. |
| TA374 (TA258) 2015 (2012)   | Somatic             | Erlotinib | Treating non-small cell lung cancer that has progressed after chemotherapy | Optimised | Optimised recommendation for erlotinib, only if the company provides erlotinib with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 258. Sections 1.1–1.5 of TA374 summarise guidance for usage. |
| TA416 2016                  | Somatic             | Osimertinib | Locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer (CDF) | Recommended | Recommended in line with clinical practice for use within cancer drugs fund only if the conditions in the managed access agreement for osimertinib are followed. |
| TA429 2017                  | Somatic             | Ibrutinib alone | Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation | Recommended | Recommended in line with marketing authorisation and following agreement of a patient access scheme. |

Low-density lipoprotein concentrations are persistently above the thresholds specified despite maximal tolerated lipid-lowering therapy. That is, either the maximum dose has been reached, or further titration is limited by intolerance (as defined in the NICE guideline for familial hypercholesterolaemia). The company provides evolocumab with the discount agreed in the patient access scheme.

Compiled from the full list of recommendations downloaded from [www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/summary-of-decisions](http://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/summary-of-decisions) [Accessed 3 April 2017]. Only the most recent recommendation for each technology is outlined in full (others referenced in brackets).
For effective application of pharmacogenetic testing, the likelihood and severity of the predicted adverse outcome must be balanced against the risk of avoiding use of an effective drug. In many cases further research is required to inform these decisions. The Clinical Pharmacogenomics Implementation Consortium (CPIC) are collating and curating such evidence, in a standardised format to assist with this.

Health economics impact

Individual benefits are clear regarding many of the applications described in this article. However, there are cost implications in identifying and testing the at-risk individual or population. Therefore, another essential component in the required evidence base is health economic analysis. This varies by condition, intervention and outcome; Peters et al provide an overview of the considerations in the case of monogenic diabetes. 

Conclusions

Technological advances and the dramatically reduced costs of DNA sequencing have resulted in increasing ‘mainstreaming’ of genetic testing into routine practice and the prospect of WGS becoming part of NHS diagnostics. Clinicians need to understand the role of genomic medicine in their specialty, in offering prompt and precise diagnosis for patients and in directing management decisions. Detailed clinical information and multidisciplinary input remains vital for variant interpretation.

The knowledge gained from genomics and personalised medical approaches is exciting. A number of applications are in current practice and these are likely to increase exponentially as WGS becomes embedded in routine patient care. Analysis of the evidence, from a clinical and health economic perspective, is pivotal to the ongoing success of the genomics era.

Conflicts of interest

All authors are currently working for Genomics England as part of the 100,000 Genomes Project.

Acknowledgments

The authors would like to thank Genomics England for providing a graphic regarding whole genome sequencing that was used to produce Fig 1.

References

1 Davies SC. Annual report of the Chief Medical Officer 2016: Generation Genome. London: Department of Health, 2017.
2 NHS England Creating a genome medicine service to lay the foundations to deliver personalised interventions and treatments. Leeds: NHS England, 2017.
3 National Human Genome Research Institutte. The Human Genome Project completion: frequently asked questions. Bethesda, MD: NHGRI, 2003. www.genome.gov/11006943/human-genome-project-completion-frequently-asked-questions/ [Accessed 15 September 2017].
4 Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860–921.
5 National Human Genome Research Institute. DNA Sequencing costs data. Bethesda, MD: NHGRI, 2016. www.genome.gov/sequencingcostsdata/ [Accessed 15 September 2017].
6 Rare Disease Day, What is a rare disease? www.rarediseaseday.org/article/what-is-a-rare-disease [Accessed 15 September 2017]
7 Department of Health. UK strategy for rare diseases. London, 2013.
8 Abbosh C, Birkbak NJ, Wilson GA et al. Phylogenetic ctdNA analysis depicts early-stage lung cancer evolution. Nature 2017;545:446–51.
9 Green RC, Berg JS, Grody WW et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565–74.
10 Richards S, Aziz A, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Medical Genetics and Genomics. Am J Hum Genet 2015;10:5–43.
11 Genome Aggregation Database, gnomAD browser. http://gnomad.broadinstitute.org/ [Accessed 15 September 2017].
12 Genomics England. The 100,000 genomes project. www.genomesengenland.co.uk/the-100000-genomes-project/ [Accessed 15 September 2017].
13 NHS England. Personalised medicine. www.england.nhs.uk/ourwork/qual-clin-lead/personalisedmedicine/ [Accessed 15 September 2017].
14 Neil HAW, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000;321:148.
15 Chapman PB, Heskel A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–16.
16 Biomarin Pharmaceuticals. Roadmap to a new therapy: understanding achondroplasia and the clinical trial process. London: Biomarin Pharmaceuticals, 2016. Available online at www.biomarin.com/pdf/BNM111_InfoGraphic_Poster_web_022516.pdf [Accessed 15 September 2017].
17 Fuji T, Komatsu Y, Yasoda A et al. Circulating C-type natriuretic peptide (CNP) rescues chondrodysplastic CNP knockout mice from their impaired skeletal growth and early death. Endocrinology 2010;151:4381–8.
18 Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568–79.
19 Clinical Pharmacogenomics Implementation Consortium. https://cpicpgx.org/ [Accessed 15 September 2017].
20 Peters IL, Anderson R, Hyde C. Development of an economic evaluation of diagnostic strategies: the case of monogenic diabetes. BMJ Open 2013;3:e002905.

Address for correspondence: Dr Helen Brittain, Clinical Genetics, Great Ormond Street Hospital For Children NHS Trust, Level 4, Barclay House, Great Ormond Street, London WC1N 3JH, UK.
Email: helen.brittain@genomicsengland.co.uk